Silver Book Fact

Drugs like bevacizumab- designed to impede the growth of blood vessels and tumors- can cost more than $100,000 per patient. 

Ubel, Peter A., Scott R. Berry, Eric Nadler, Chaim M. Bell, Michael A. Kozminski, Jennifer A. Palmer, William K. Evans, Elizabeth L. Strevel, and Peter J. Neumann. In A Survey, Marked Inconsistency In How Oncologists Judged Value Of High-Cost Cancer Drugs In Relation To Gains In Survival. Health Aff. 2012; 31(4): 709-717. http://content.healthaffairs.org/content/31/4/709.abstract

Reference

Title
In A Survey, Marked Inconsistency In How Oncologists Judged Value Of High-Cost Cancer Drugs In Relation To Gains In Survival
Publication
Health Aff
Publisher
Project HOPE
Publication Date
2012
Authors
Ubel, Peter A., Scott R. Berry, Eric Nadler, Chaim M. Bell, Michael A. Kozminski, Jennifer A. Palmer, William K. Evans, Elizabeth L. Strevel, and Peter J. Neumann
Volume & Issue
Volume 31, Issue 4
Pages
709-717
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Mortality rates for colorectal cancer have declined over the past 2 decades and have had a steeper decline in the most recent time period (1.8% per year from 1985-2002 compared…  
  • More than half of cancer deaths in the U.S. are due to preventable causes.  
  • Five-year Relative Survival (%) during Three Time Periods by Cancer Site  
  • Since 1991 the cancer death rate has fallen by 20 percent.  
  • Cancer mortality declined more than 2% in 2003, a continuation of the decline that began in 1990.